Insider / INSMED Inc
Bonstein Sara
Chief Financial Officer at INSMED Inc
- Company
- INSMED Inc
- First filing on record
- January 6, 2026
- Latest trade on record
- June 11, 2026
- SEC filings
- EDGAR ↗
Bonstein Sara, Chief Financial Officer at INSMED Inc, has disclosed 10 transactions in XLO, INSM since January 6, 2026: 0 purchases (0 open-market buys) and 6 sales, worth about $2.1M at the reported prices. The latest was filed June 12, 2026, 1 day after the trade.
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
In the last 12 months Bonstein Sara made no purchases and 6 sales worth $2.1M, plus 4 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Bonstein Sara has traded 1 stock on record; the largest by dollars is INSM.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
0 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 6 | 16,066 | $2.1M |
| A | Grant or award | 4 | 47,923 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 10 | 0 | 6 · $2.1M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| INSM | Sell S | June 3, 2026 | June 5, 2026 | 2d | 2,404 | $102 | $246K | Form 4 ↗ | ||
| INSM | Sell S | May 13, 2026 | May 15, 2026 | 2d | 8,272 | $116 | $961K | Form 4 ↗ | ||
| INSM | Sell S | February 3, 2026 | February 4, 2026 | 1d | 748 | $156 | $117K | Form 4 ↗ | ||
| INSM | Sell S | January 8, 2026 | January 8, 2026 | 0d | 1,447 | $174 | $252K | Form 4 ↗ | ||
| INSM | Sell S | January 7, 2026 | January 8, 2026 | 1d | 1,678 | $175 | $294K | Form 4 ↗ | ||
| INSM | Sell S | January 6, 2026 | January 8, 2026 | 2d | 1,517 | $173 | $263K | Form 4 ↗ | ||
| INSM | Other A | January 2, 2026 | January 6, 2026 | 4d | 31,280 | — | — | derivative | Form 4 ↗ | |
| INSM | Other A | January 2, 2026 | January 6, 2026 | 4d | 5,645 | — | — | Form 4 ↗ | ||
| INSM | Other A | January 2, 2026 | January 6, 2026 | 4d | 5,998 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 12, 2026 | Form 4 | 0001193125-26-269396 | 1 | published | EDGAR ↗ |
| June 5, 2026 | Form 4 | 0001604019-26-000010 | 1 | published | EDGAR ↗ |
| May 15, 2026 | Form 4 | 0001604019-26-000008 | 1 | published | EDGAR ↗ |
| February 4, 2026 | Form 4 | 0001604019-26-000006 | 1 | published | EDGAR ↗ |
| January 8, 2026 | Form 4 | 0001604019-26-000004 | 3 | published | EDGAR ↗ |
| January 6, 2026 | Form 4 | 0001604019-26-000002 | 3 | published | EDGAR ↗ |
Other insiders at INSMED Inc
- Lewis William Chair and CEO 136 rows
- Flammer Martina M.D. Chief Medical Officer 67 rows
- Smith Michael Alexander Chief Legal Officer 30 rows
- Frankenfield Christopher James Chief Financial Officer 21 rows
- Adsett Roger Chief Operating Officer 20 rows
- Russo Rene PRESIDENT AND CEO 20 rows
- Schaeffer Orlov S Nicole Chief People Strategy Officer 15 rows
- Luptakova Katarina CHIEF MEDICAL OFFICER 14 rows
- Brennan Kevin M. SVP, FINANCE AND ACCOUNTING 11 rows
- SHAROKY MELVIN MD Director 9 rows
Everyone on file, with contracts and lobbying under the company's name: INSMED Inc.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 10 | January 6, 2026 | June 12, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.